Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nevirapine +/- Zidovudine in Asymptomatic HIV-1
NCT00002324Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nevirapine in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: CD4 T-cell count at 6 months, CD4 T-cell percentage at 6 months and 1 more. Status: completed.
02
Drugs
nevirapine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002324.